Monitor for continued insider selling patterns and upcoming earnings or clinical trial updates; no immediate red flag, but sustained selling could signal muted confidence if not explained by 10b5-1 plans.
Price Chart
Executive Summary
Multiple C-suite executives at Caribou Biosciences (CRBU) sold shares in a coordinated cluster over a 7-day window, totaling approximately $35,500 in sales. On the same dates, these insiders also received substantial stock awards (totaling hundreds of thousands of shares), indicating the sales were part of pre-arranged 10b5-1 plans or compensation-related exercises. The activity aligns with recent insider selling trends and appears routine rather than reactive to material non-public information.
Key Financial Metrics
Key Facts
- Four C-suite executives sold shares on February 24, 2026, at $1.96 per share, totaling $35,454.44 in aggregate.
- On February 20, 2026, the same executives received stock awards ranging from 45,000 to 55,000 shares, valued at zero because they are newly granted.
- The sales are likely part of pre-scheduled 10b5-1 plans or option exercises tied to compensation, not discretionary market timing.
- Total value of insider sales in the last 30 days is $35K, consistent with this cluster.
- No open-market buying activity observed in the cluster.
Financial Impact
$35,454 in insider sales; offset by $0 cost basis in awards received
Risk Factors
- Perception of insider pessimism if sales are not clearly tied to pre-arranged plans.
- Potential dilution from large stock awards if not offset by performance-based vesting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-CRBU-1771984517304 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | 8-K | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 11, 2026 16w ago | Press Release | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 5, 2026 16w ago | DEFA14A | $1.84 $1.83 | ▼ −0.54% | ▼ −2.17% | $1.23 (−33.42%) |
Apr 24, 2026 22w ago | DEFA14A | $2.13 $2.16 | ▲ +1.41% | ▼ −3.55% | $1.23 (−42.49%) |
Mar 5, 2026 30w ago | 8-K | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Mar 5, 2026 30w ago | Press Release | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Feb 28, 2026 30w ago | Institutional Cluster | $1.84 $1.72 | ▼ −6.52% | ▲ +1.42% | $1.23 (−33.42%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access